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Abstract The human factor H-related proteins FHR-3 and
FHR-4 are members of a family of proteins related to the
complement factor H. Here, we report that the two proteins bind
to the C3d region of complement C3b. The apparent KA values
for the interactions of FHR-3 and FHR-4 with C3b are 7.5U106
M31 and 2.9U106 M31, respectively. Binding studies performed
with C3b-coated pneumococci confirmed the results obtained
with the biosensor system. A C-terminal construct of factor H
showed similar binding characteristics. The interaction of FHR-
3, but not of FHR-4, with opsonised pneumococci was inhibited
by heparin.
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1. Introduction
The human factor H-related proteins 3 and 4 (FHR-3 and
FHR-4) are members of a group of plasma proteins structur-
ally and immunologically related to complement factor H
(FH) [1,2]. The cDNAs encoding FHR-3 and FHR-4 were
isolated from a human liver cDNA library and are 1269
and 1315 bp in size. The genes for FHR-3 and FHR-4 have
recently been mapped to the ‘regulators of complement acti-
vation’ (RCA) gene cluster on human chromosome 1 [3]. The
corresponding proteins are composed of 331 amino acids and
display a striking similarity to each other. The FHR-3 protein
exists in several glycosylated forms in human plasma with a
molecular mass ranging from 45 to 56 kDa, while the FHR-4
protein forms a 86 kDa homodimer and is a constituent of
plasma and triglyceride-rich lipoproteins [1,2].
The factor H protein family consists of factor H, the factor
H-like protein 1 (FHL-1), which is derived from a di¡erently
processed transcript of the factor H gene [4^6], and four
FHRs (FHR-1^FHR-4) [7]. All members of this family are
exclusively arranged in short consensus repeat (SCR) do-
mains, also called complement control protein modules.
FHR-1, FHR-3 and FHR-4 are composed of ¢ve SCRs, while
FHR-2 contains four, FHL-1 seven and factor H 20 SCRs [7].
SCR domains are also found in other complement and non-
complement proteins [8].
The biological functions of factor H and FHL-1 in comple-
ment regulation are well established [9,10]. Both plasma pro-
teins control alternative pathway complement activation in
the £uid phase and factor H may function in the discrimina-
tion between self and non-self structures. Factor H and FHL-
1 act as cofactors for the serine protease factor I in the pro-
teolytic inactivation of C3b [9^13]. Both proteins also inhibit
formation of the C3 convertase C3bBb by competing with
factor B for binding to C3b and by accelerating the dissocia-
tion of the C3bBb complex [14,15]. Factor H allows for acti-
vation of the alternative pathway on foreign cells and par-
ticles, while it inhibits activation on host structures,
probably by binding to C3b in combination with negatively
charged glycosaminoglycans (e.g. heparan sulfate, chondroitin
sulfate) or sialic acids [16^19]. Interaction of factor H with
C3b is an important step in alternative pathway regulation
and a total of three C3b binding sites have been localised
on the factor H protein, implying a complex interaction of
cooperative binding sites between factor H and C3b [20^22].
As the physiological functions of FHR-3 and FHR-4 are
not yet known, our aim was to analyse whether the proteins
interact with the central complement component C3b and
possibly play a role in complement regulation. We used the
surface plasmon resonance technique to analyse FHR-3 and
FHR-4 binding to C3b and identi¢ed both proteins as ligands
for C3b. The binding sites were mapped to the C3d region of
C3b. Both FHR-3 and FHR-4 bound to C3b-opsonised pneu-
mococci, suggesting that they could regulate complement-
mediated processing of foreign antigens.
2. Materials and methods
2.1. Expression and puri¢cation of FHR-3 and FHR-4
Subcloning of FHR-3 cDNA DOWN16 into the baculovirus ex-
pression vector pBSV-8His [1,23], recombinant expression and puri¢-
cation of FHR-3 and FHR-4 was performed as described recently
[24]. Spodoptera frugiperda cells (Sf9) were grown at 28‡C in mono-
layer culture in protein-free Express medium (BioWhittaker, Verviers,
Belgium) in the presence of streptomycin (100 Wg/ml), penicillin (100
U/ml) and amphotericin B (250 ng/ml) (Life Technologies, Eggenstein,
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Germany). Sf9 cells were infected with recombinant virus using a
multiplicity of infection of ¢ve. The culture supernatant was harvested
after 9 days and recombinant proteins were puri¢ed by nickel chelate
chromatography as described [23]. Puri¢ed recombinant proteins were
dialysed against 1/3 VBS (50 mM NaCl, 3.3 mM barbiturate, pH 7.5)
overnight and concentrated using an Ultrafree-15 Centrifugal Filter
Device Biomax-5K (Millipore, Bedford, MA, USA). The protein con-
centration was measured with the BCA Protein Assay reagent (Pierce
Chemical, Rockford, IL, USA).
2.2. Puri¢cation of complement components
Plasma proteins C3, factors B, D, H and I were puri¢ed from
human plasma and C3b was generated as described previously
[25,26]. C3d was prepared from puri¢ed human C3 by a modi¢cation
of the method of Eggertsen et al. [27]. Brie£y, C3 at a concentration
of 4 mg/ml in VBS was incubated with TPCK-treated trypsin (Sigma,
St. Louis, MO, USA) for 2 h at 37‡C at an enzyme/substrate ratio of
1:60. The reaction was stopped by addition of soybean trypsin inhib-
itor (Sigma) at a ratio of 1:3 trypsin to inhibitor (w/w). C3d was
isolated using a Mono Q column (Pharmacia, Uppsala, Sweden)
with a 0.1^0.4 M NaCl gradient in 0.025 M Tris-HCl, pH 8.3. In
accordance with the ¢ndings of Eggertsen et al. [27], C3d was eluted
in an asymmetrical peak shortly before the major peak consisting of
the higher molecular weight products and appeared under reducing
conditions by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) analysis as a triplet of bands with apparent mo-
lecular masses of 30^35 kDa. The identity of all three bands as C3d
was con¢rmed by their reactivity with the previously described C3d-
speci¢c monoclonal antibody 4C2 [25].
2.3. SDS-PAGE and Western blot analyses
Recombinant FHR-3 and FHR-4 puri¢ed by nickel a⁄nity chro-
matography and human plasma were subjected to SDS-PAGE using
10% or 12% gels and detected by Western blotting using polyclonal
antisera raised against recombinant FHR-3 or FHR-4 [24,28].
2.4. Heparin a⁄nity chromatography
Five ml of normal human serum diluted in equilibration bu¡er (1/
3UVBS, 50 mM NaCl, 0.05% azide) was applied on a 1 ml agarose
column coupled with 10 mg porcine heparin (HiTrap Heparin, Phar-
macia). Samples were passed over the column ¢ve times at a £ow rate
of 1 ml/min at room temperature and the fall-through was collected.
After washing with 5 ml of equilibration bu¡er, elution was per-
formed by a linear NaCl gradient from 50 mM to 1 M NaCl at a
£ow rate of 1 ml/min in 20 min. Fractions of 0.5 ml were collected
and the column was regenerated with 5 ml of 2 M NaCl followed by
15 ml of equilibration bu¡er. The elution fractions were subjected to
SDS-PAGE and Western blotting.
2.5. Analysis of interaction with C3b and C3d using surface plasmon
resonance
Surface plasmon resonance measurements were performed using a
Biacore 2000 instrument and BIAevaluation software V 3.0 (Biacore
AB, Uppsala, Sweden). C3b was immobilised on a carboxylated dex-
tran CM5 sensor chip (Biacore AB, Uppsala, Sweden) either by using
the amine coupling procedure according to the protocol of the man-
ufacturer or by enzymatic cascade formation of C3b in the presence of
1 mM Ni2 by sequential addition of puri¢ed C3, factor B and factor
D ([22] and Jokiranta et al., manuscript in preparation). Brie£y, 20 Wg
of C3, 5 Wg of factor B and 0.05 Wg of factor D were ¢rst injected
together, followed by 3^5 cycles of injecting factors B and D or C3
sequentially to generate alternative pathway C3 convertases and sub-
sequently C3b molecules bound to the surface via the physiological
ester or amide bond. Binding analyses with recombinant FHR-3 and
FHR-4 were performed using 1/3 VBS bu¡er at a £ow rate of 5 Wl/min
and at 30 Wl/min for kinetic analyses. After each experiment, the sur-
face was regenerated by passing 30^50 Wl of regeneration bu¡er (2 M
NaCl in acetate bu¡er, pH 4.6) through the £ow cell. For analysis of
interaction with C3d, the protein was bound to the pre-activated CM5
chip with the standard amine coupling method provided by the man-
ufacturer.
2.6. Radiolabelling of C3b and cofactor analysis
Human C3b (200 Wg; from Advanced Research Technologies, San
Diego, CA, USA) was labelled with 125I using the Iodogen technique.
The cofactor assay was performed as described using either puri¢ed
factor I or factor H-de¢cient serum (FHDS) as a source for factor I
[29]. The FHDS (kindly provided by Drs. Marina Noris and Silvia
Orisio, Mario Negri Institute, Bergamo, Italy) was diluted 1:200 in
VBS. The radiolabelled C3b was added to factor I or FHDS in the
absence or presence of a cofactor. Factor H was added to a ¢nal
concentration of 40, 4, 0.4 and 0 Wg/ml for titrating its cofactor ac-
tivity in this assay system. A concentration of 4 Wg/ml was then used
as a basic level to measure enhancement of cofactor activity by FHRs.
Recombinant FHR-3 and FHR-4 were added to ¢nal concentrations
of 100 and 200 Wg/ml. The ¢nal reaction volume was 40 Wl. C3b
incubated with VBS or factor H-de¢cient plasma in the same dilution
served as negative controls. The mixture was incubated at 37‡C for
4 h, reduced and analysed by SDS-PAGE. Gels were ¢xed for 10 min
in 10% acetic acid, dried and autoradiographed.
2.7. Binding of FHR-3 and FHR-4 to C3b-opsonised pneumococci
Heat-inactivated pneumococci (isolated from a case of acute otitis
media) were coated with C3b by the following procedure: particles
were incubated with 1 mg C3, 0.1 mg factor B and 2 Wg factor D for
20 min at 30‡C in VBS containing 0.1% gelatin and 2.5 mM NiCl2
(GVB-Ni). After washing twice with GVB-Ni, the cells were treated
with factors B and D for 4 min at 30‡C, washed with GVB-EDTA (2
mM EDTA in GVB) and incubated with 1 mg C3 (20 min at 30‡C).
After repetition of the last cycle with factors B, D and C3, the par-
ticles were washed and used as a 10% solution. In the binding assay,
the indicated amounts of opsonised pneumococci were incubated (15
min at 37‡C) with the radiolabelled FHRs (60 000 cpm) or a C-termi-
nal recombinant fragment of factor H (SCRs 15^20) in a total volume
of 100 Wl GVB. Particle-associated factor H was separated from un-
bound ligand by centrifuging the mixtures through 20% sucrose. After
cutting o¡ the pellets, the binding of the FHR/factor H proteins was
calculated as a percentage of the total radioactivity input. All experi-
ments were performed a least in duplicate. For the heparin inhibition
assay, the indicated amounts of heparin (Sigma, St. Louis, MO, USA)
were added to the reaction mixture.
3. Results
3.1. Structure of FHR-3 and FHR-4
As FHR-3 and FHR-4 are related in structure and sequence
to each other and to FH, we were interested in studying the
function of these proteins and asked whether the two proteins
display complement regulatory activities. Both FHR-3 and
FHR-4 are composed of ¢ve SCR units, a structural compar-
ison of the two proteins is shown in Fig. 1A. SCRs 1^3 of
FHR-3 and FHR-4 show similarity with SCRs 6, 7, 8 and 6,
8, 9 of FH, respectively. SCRs 4^5 of FHR-3 and FHR-4 are
almost identical to each other and display a high degree of
similarity with the C-terminal SCRs 19 and 20 of FH [7].
3.2. Heparin a⁄nity puri¢cation of FHR-3 from human serum
Binding of recombinant FHR-3 to heparin has been de-
scribed recently [19]. To exploit this property, we used heparin
a⁄nity chromatography to enrich the native FHR-3 protein
from human plasma. FHR-4 did not bind to heparin and its
homodimeric form of 86 kDa was found in the fall-through
and wash fractions (Fig. 1B) [2,24]. FHR-3 and FH bound to
the heparin matrix and were eluted with a linear NaCl gra-
dient. Both proteins were detected in the elute fractions by
Western blotting (Fig. 1C). The relative mass of the recombi-
nant FHR-3 protein ranges from 45 to 56 kDa, as it is ex-
pressed in di¡erently glycosylated forms (Fig. 1C). These re-
sults showed a di¡erence in the heparin binding properties of
FHR-3 and FHR-4.
3.3. Binding analysis of FHR-3 to C3b and C3d
We used the surface plasmon resonance technique to ana-
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lyse the interaction of FHR-3 and FHR-4 with C3b. C3b was
bound to the sensor chip surface either by standard amine
coupling or by a new enzymatic method [22]. To further local-
ise the binding site within the C3b molecule, the fragments
C3c and C3d were prepared and immobilised onto the sensor
chip by amine coupling. We ¢rst analysed the interaction of
£uid phase FHR-3 with C3b bound to the solid phase. A
representative experiment is shown in Fig. 2. Binding of
FHR-3 to C3b corresponded to an increase of approximately
3000 resonance units (Fig. 2A, left panel). After 240 s, the
FHR-3 solution was replaced with bu¡er and the dissociation
of the FHR-3/C3b complex was followed. Addition of FHR-3
to a non-coated £ow cell showed only a bulk e¡ect (control).
A speci¢c binding curve, as shown in the right part of Fig.
2A, was obtained by subtraction of the background values.
For a more detailed localisation of the interacting region with-
in the C3 molecule, C3c and C3d were used as ligands instead
of C3b. No binding to C3c was detected (data not shown), but
the interaction of FHR-3 with C3d was similar to the inter-
action with C3b (Fig. 2B).
3.4. Binding of C3b/C3d to immobilised FHR-3
In order to con¢rm the interaction of FHR-3 with C3b and
C3d, a reverse setting was used, where FHR-3 was immobi-
lised on the chip surface and C3b or C3d was added as £uid
phase ligands. With this approach, similar interactions as de-
scribed above were observed for both C3b (Fig. 2C) and C3d
(Fig. 2D). These results show that FHR-3 binds to C3b and
C3d and suggest a single interaction site located within the
C3d region.
3.5. Binding of FHR-4 to C3b and C3d
We next analysed the interaction of FHR-4 with C3b and
C3d immobilised to the chip surface. Similar to FHR-3, FHR-
4 was found to bind to C3b (Fig. 3A) and C3d (Fig. 3B) but
not to C3c (data not shown). In the reverse setting, binding
was observed when FHR-4 was coupled to the chip surface
and C3b and C3d were added in the £uid phase (Fig. 3C and
3D).
The apparent overall association (on-rate) and dissociation
(o¡-rate) rates of FHR-3 and FHR-4 were measured for in-
teraction with both C3b and C3d. For both proteins, the
kinetics were analysed using a 1:1 binding model with mass
transfer. This model was used according to the observation
that recombinant FHR-4 exists predominantly in a mono-
meric form [2,24]. The apparent a⁄nity constants were calcu-
lated from the measured rates and are shown in Table 1. The
apparent association and dissociation rates of the FHR-3/C3b
complex obtained either using C3b with amine coupling or
after coupling with the enzymatic method were within the
same range (Table 1). The values measured for the on-rate
and o¡-rate of FHR-4/C3b were similar to the results ob-
tained with FHR-3 (Table 1). In all cases, similar results
were obtained with both coupling methods and independently
of which of the ligands was immobilised to the chip surface.
3.6. E¡ect of FHRs on the factor I-mediated degradation of
C3b
We next assessed whether FHR-3 and FHR-4 act as cofac-
tors for the factor I-mediated C3b inactivation. To this end,
recombinant FHR-3, FHR-4 or puri¢ed factor H together
with [125I]C3b were incubated with factor I. The direct cofac-
tor activity of the FHRs was very low, being detectable only
at a high and non-physiological concentration of 400 Wg/ml
(data not shown). We then used FHDS as a source for factor
I. In this situation, the cofactor activity was considerably
Fig. 1. Structural comparison and heparin binding characteristics of native FHR-3 and FHR-4 proteins. A: The SCR domain structure of
FHR-3 and FHR-4 is shown. SCRs are numbered consecutively and the percentage of amino acid similarity of single SCRs is indicated. B:
Five ml of diluted human plasma was applied onto a heparin agarose column and after washing, bound proteins were eluted with a linear salt
gradient. Analysis of the fall-through (FT) and wash fractions. FHR-4 protein did not bind heparin and was detected with anti-FHR-4 (lane 1)
antiserum. For the detection of FHR-3, anti-FHR-3 (lanes 2^7) antiserum was used for the fall-through (FT) and wash fractions. The doublet
band of about 43 kDa (lane 2) was not further analysed. C: Detection of FHR-3 in the elute fractions using anti-FHR-3 antiserum. Due to
cross-reactivity, FH was also detected in the eluted fractions. The mobility of the size markers is indicated in kDa.
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Fig. 2. Determination of interactions of FHR-3 with C3b and C3d by surface plasmon resonance. Interactions of recombinant FHR-3 with
C3b either bound to the solid phase (A) or in the £uid phase (C) and with C3d bound to the solid phase (B) or in the £uid phase (D) were an-
alysed with the Biacore equipment. Resonance units are shown as a function of time. The left part displays the binding curves in comparison
with the control £ow cell (where no coating was performed), while in the right part, the control was subtracted. The arrow indicates the time
of injection of the ligand.
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higher when FHR-3 and FHR-4 were added (Fig. 4). Thus, it
seemed that a component in the FHDS was needed for the
cofactor activity. As the FHDS contains trace amounts of
FHL-1, which is also a cofactor for factor I in the cleavage
of C3b [11,13], we considered the possibility that FHR-3 and
FHR-4 promoted the cofactor activity of FHL-1 in the assay.
This was con¢rmed when puri¢ed factor H was added to the
reaction mixture. We observed that both FHR-3 and FHR-4
enhanced the cofactor activity of factor H. The addition of
recombinant proteins FHR-3 and FHR-4 promoted the cleav-
Fig. 3. Interactions of FHR-4 with C3b and C3d determined by surface plasmon resonance. Interactions of recombinant FHR-4 with C3b ei-
ther on the solid phase (A) or in the £uid phase (C) and with C3d on the solid phase (B) or in the £uid phase (D) were analysed similarly as
described for Fig. 2.
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age of the 112 kDa KP-chain of C3b into two fragments of 68
and 41/43 kDa (Fig. 4).
3.7. Binding of FHR-3 and FHR-4 to C3b-opsonised
pneumococci
To con¢rm the results obtained with the biosensor system
and to assess binding of FHRs to C3b in a more physiological
situation, pneumococci were opsonised with C3b and binding
of FHR-3 and FHR-4 were examined. As shown in Fig. 5A,
both FHR-3 and FHR-4 bound to C3b on pneumococci. A
similar binding was seen with a C-terminal construct SCR 15-
20 of factor H, which is known to contain one binding site for
C3b/C3d. FHR-3 showed a stronger binding to the C3b pneu-
mococci surface (up to 24.3% binding) than the FH construct
SCR 15-20 (9.6%) or FHR-4 (7.5%). The negative control
[125I]BSA showed no binding. To test if the enhanced binding
of FHR-3 to the pathogen surface was due to an interaction
with its heparin binding site, the e¡ect of heparin on the
interaction was investigated. As shown in Fig. 5B, the addi-
tion of heparin reduced the binding of FHR-3 to the C3b-
coated pneumococcal surface to the level of FHR-4. This
result suggests that FHR-3 uses both its C3b/C3d and heparin
binding sites for the interaction with the surface of the opson-
ised pneumococci.
4. Discussion
Although four human factor H-related molecules have been
identi¢ed and cloned, little is known about the biological
functions of these proteins. Both FHR-3 and FHR-4 are
present in the free form in human plasma and in addition,
FHR-4 is a constituent of human lipoproteins [2]. Due to their
Table 1
Quantitative analysis of the interactions between FHR-3/FHR-4 and fragments of C3
Solid phase Fluid phase Apparent ka (1/Ms) Apparent kd (1/s) Apparent KA (1/M) Apparent KD (M)
C3b (Enz)a FHR-3 2.0U104 2.7U1033 7.5U106 1.3U1037
C3b (Amine)b FHR-3 1.7U104 1.4U1033 1.3U107 8.0U1038
C3d FHR-3 1.8U104 1.6U1033 1.2U107 8.7U1038
C3b (Enz)a FHR-4 1.6U104 5.4U1033 2.9U106 3.4U1037
C3b (Amine)b FHR-4 2.3U104 5.6U1033 4.2U106 2.4U1037
C3d FHR-4 2.0U104 5.1U1033 3.9U106 2.6U1037
Association and dissociation rates were determined by surface plasmon resonance analysis. The equilibrium constants were calculated from the
rate constants.
aEnz: Protein coupling of C3b onto the chip surface was performed by an enzymatic procedure.
bAmine: C3b was immobilised using the amine coupling method.
Fig. 4. Factor I cofactor assay. The ability of recombinant FHR-3
and FHR-4 proteins to promote factor I-mediated cleavage of C3b
was assayed in human factor H-de¢cient plasma. Recombinant
FHR-3 or FHR-4 and puri¢ed factor H were added together with
radiolabelled [125I]C3b to diluted human factor H-de¢cient plasma.
After incubation for 4 h, the samples were separated by SDS-PAGE
and the gels were analysed by autoradiography. C3b (incubated in
VBS, lane 1) and C3b in the diluted FHDS (lane 2) served as nega-
tive controls. With the positive control factor H (lane 3), the C3b
K-chain was cleaved and products of 41, 43 and 68 kDa were de-
tected. A titration of factor H activity is shown in lanes 3^5. A sim-
ilar cleavage pattern was seen using FHR-3 (lane 10) and FHR-4
(lane 11) as cofactors, although the activity was weak. The activity
of factor H (4 Wg/ml) was clearly enhanced by the addition of
FHR-3 (200 Wg/ml in lane 6 and 100 Wg/ml in lane 7) or FHR-4
(200 Wg/ml in lane 8 and 100 Wg/ml in lane 9).
Fig. 5. Interaction of FHR-3, FHR-4 and a C-terminal fragment of
factor H with C3b-coated pneumococci. A: Opsonised pneumococci
were incubated with radiolabelled FHR-3, FHR-4 or a C-terminal
construct SCR 15-20 of factor H for 15 min at 37‡C. BSA was
used as a control. B: The in£uence of increasing amounts of hepa-
rin (0^300 Wg/ml) on the interaction between FHR-3 and FHR-4
and opsonised pneumococci (5%) was measured.
FEBS 22986 26-11-99
J. Hellwage et al./FEBS Letters 462 (1999) 345^352350
structural similarity with other C3b binding proteins such as
factor H, CR1 (CD35), CR2 (CD21) and MCP (CD46), we
have analysed whether FHR-3 and FHR-4 share properties
with these complement regulators or receptors. Using biosen-
sor real time measurements, we observed that recombinant
FHR-3 and FHR-4 bound to the complement component
C3b and to its proteolytic cleavage fragment C3d. As binding
to C3c was excluded and as both FHR-3 and FHR-4 bound
to C3b and C3d with similar a⁄nities, we propose the pres-
ence of a single binding site within the C3d region.
In experiments performed to test functional similarity of the
FHRs to factor H, neither FHR-3 nor FHR-4 showed decay
accelerating activity for C3bBb convertases assembled on
sheep red blood cells (data not shown). We also tested the
cofactor activity for C3b inactivation by factor I. The proteins
alone displayed no signi¢cant activity. However, when limited
amounts of factor H/FHL-1 were present, the FHRs had a
promoting e¡ect on the inactivation of C3b (Fig. 4). This
suggests that binding of FHR-3 and FHR-4 to C3b a¡ects
its conformation and sensitivity to inactivation by factor I.
Semiquantitative analysis with the phosphorimaging software
showed that FHR-3 had about 54% of the activity of FHR-4
in this £uid phase assay (Fig. 4). Subsequently, we tested
binding of FHRs to C3b on a pathogen surface as this rep-
resents a more physiological situation. Both FHRs bound to
C3b deposited on pneumococci (Fig. 5A). In this situation,
FHR-3 bound more strongly than FHR-4. However, the in-
teraction of FHR-3, but not of FHR-4, with the C3b-coated
pathogen surface could be inhibited by the addition of heparin
(Fig. 5B). This indicates that the two proteins have di¡erent
binding characteristics under physiological conditions.
The high degree of relatedness of FHR-3 and FHR-4 is in
agreement with the functional similarity as both proteins bind
to C3b and C3d. In human plasma, the concentration of
FHR-3 is low and native FHR-3 protein can only be detected
by means of immunopuri¢cation [24] or by heparin a⁄nity
chromatography (Fig. 1). In contrast, neither the recombinant
[19] nor the native form of FHR-4 interacts with heparin (Fig.
1). The di¡erence in the ability to bind heparin represents one
clear functional di¡erence between FHR-3 and FHR-4 and
suggests a di¡erent distribution of these proteins in vivo.
The di¡erent localisation is also supported by the association
of native FHR-4 [2] but not of FHR-3 with chylomicrons and
triglyceride-rich lipoproteins. An interaction with lipids has
also been shown for complement regulators, e.g. C4b binding
protein and clusterin [30,31], as well as for the FHRs FHR-1
and FHR-2 [32].
We have demonstrated binding of FHR-3 and FHR-4 to
the central complement component C3b. Proteolytic cleavage
of C3b results ¢rst in iC3b and subsequently in the large C3c
and the small C3dg fragment. FHR-3 and FHR-4 bound to
the C3d (Fig. 2 and 3) but not to the C3c fragment of C3
(data not shown). An interaction with the C3d region has also
been shown for the complement receptors CR1 and CR2 and
for the regulator factor H [33]. For factor H, two interaction
sites on the KP-chain of human C3 have been described in
detail. One site is represented by residues 727^768 of the
C3c fragment, while a second site was mapped to the C3d
region of residues 1199^1274 [34]. The apparent overall asso-
ciation and dissociation rates for FHR-3 and FHR-4 with
both C3b and C3d are in the same order of magnitude (Table
1). The apparent KA values for the interactions of FHR-3 and
FHR-4 with C3b are 7.5U106 M31 and 2.9U106 M31, re-
spectively. We propose a single point interaction and the lo-
cation of the interacting domain within the C3d region of
C3b. These a⁄nity constants are comparable to that obtained
for the interaction of factor H and C3d in the same system
(2.8U106 M31, [22] and Jokiranta et al., manuscript in prep-
aration).
The conservation of a C3b/C3d binding site suggests a C3
regulatory function for FHR-3 and FHR-4. Although all
three proteins exhibit overlapping functions in C3d binding,
di¡erences exist between the two FHR proteins and factor H:
(i) The homology of FHR-3 and FHR-4 with factor H ex-
cludes the complement regulatory domains of factor H which
are located within the N-terminal four SCRs of the protein
[11,12,15]. (ii) The data presented in Fig. 4 suggest that the
two FHR proteins can ‘prime’ C3b to inactivation by factor I
in the presence of a cofactor (e.g. factor H/FHL-1), although
(iii) neither FHR-3 nor FHR-4 acts as e⁄ciently as a cofactor
on their own and both proteins lack decay accelerating activ-
ity for the C3 convertase. FHR-3 and FHR-4 interact with
C3b/C3d, but they might possess additional, yet unidenti¢ed
functions. These may be dependent on their C3d binding ac-
tivity.
In conclusion, we have identi¢ed FHR-3 and FHR-4 as
new ligands for the complement component C3b and localised
their binding site to the C3d region. Their ability to bind C3b
and C3d suggests speci¢c functions in modulating the confor-
mation and stability of C3b or in the processing of C3b or
C3dg-coated particles. As C3dg has been proposed to act as
an endogenous adjuvant, it will be of interest to de¢ne a role
of these two FHR proteins at the interface between the innate
and the acquired immunity [35]. Binding to opsonised pneu-
mococci suggests that the FHRs could have a role in regulat-
ing processing of C3d-coated antigens derived from exoge-
nous or endogenous sources.
Acknowledgements: We thank Eva Kampen for expert technical assis-
tance. We are grateful to Dr. Hilkka Lankinen (Dept. of Virology,
Haartman Institute, Helsinki, Finland) for continuous help with the
Biacore equipment. This study was supported by the DAAD (J.H. is
supported by a fellowship provided by the Hochschulsonderprog-
ramm III), the Deutsche Forschungsgemeinschaft (Zi 432), the Acad-
emy of Finland, the Sigrid Juse¤lius Foundation and the Helsinki Uni-
versity Central Hospital Funds.
References
[1] Skerka, C., Ku«hn, S., Gu«nther, K., Lingelbach, K. and Zipfel,
P.F. (1993) J. Biol. Chem. 268, 2904^2908.
[2] Skerka, C., Hellwage, J., Weber, W., Tilkorn, A., Buck, F., Mar-
ti, T., Kampen, E., Beisiegel, U. and Zipfel, P.F. (1997) J. Biol.
Chem. 272, 5627^5634.
[3] Diaz-Guillen, M.A., Rodriguez de Cordoba, S. and Heine-Suner,
D. (1999) Immunogenetics 49, 549^552.
[4] Estaller, C., Schwaeble, W., Dierich, M. and Weiss, E.H. (1991)
Eur. J. Immunol. 21, 799^802.
[5] Fontaine, M., Demares, M.J., Koistinen, V., Day, A.J., Da-
vrinche, C., Sim, R.B. and Ripoche, J. (1989) Biochem. J. 258,
927^930.
[6] Zipfel, P.F. and Skerka, C. (1999) Immunol. Today 20, 135^140.
[7] Zipfel, P.F. (1999) Immunopharmacology 42, 53^60.
[8] Reid, K.B. and Day, A.J. (1989) Immunol. Today 10, 177^180.
[9] Whaley, K. and Ruddy, S. (1976) J. Exp. Med. 144, 1147^1163.
[10] Pangburn, M.K., Schreiber, R.D. and Mu«ller-Eberhard, H.J.
(1977) J. Exp. Med. 146, 257^270.
[11] Ku«hn, S., Skerka, C. and Zipfel, P.F. (1995) J. Immunol. 155,
5663^5670.
FEBS 22986 26-11-99
J. Hellwage et al./FEBS Letters 462 (1999) 345^352 351
[12] Gordon, D.L., Kaufman, R.M., Blackmore, T.K., Kwong, J. and
Lublin, D.M. (1995) J. Immunol. 155, 348^356.
[13] Misasi, R., Huemer, H.P., Schwaeble, W., Solder, E., Larcher, C.
and Dierich, M.P. (1989) Eur. J. Immunol. 19, 1765^1768.
[14] Weiler, J.M., Daha, M.R., Austen, K.F. and Fearon, D.T. (1976)
Proc. Natl. Acad. Sci. USA 73, 3268^3272.
[15] Ku«hn, S. and Zipfel, P.F. (1996) Eur. J. Immunol. 26, 2383^2387.
[16] Kazatchkine, M.D., Fearon, D.T., Silbert, J.E. and Austen, K.F.
(1979) J. Exp. Med. 150, 1202^1215.
[17] Meri, S. and Pangburn, M.K. (1990) Proc. Natl. Acad. Sci. USA
87, 3982^3986.
[18] Blackmore, T.K., Sadlon, T.A., Ward, H.M., Lublin, D.M. and
Gordon, D.L. (1996) J. Immunol. 157, 5422^5427.
[19] Blackmore, T.K., Hellwage, J., Sadlon, T.A., Higgs, N., Zipfel,
P.F., Ward, H.M. and Gordon, D.L. (1998) J. Immunol. 160,
3342^3348.
[20] Jokiranta, T.S., Zipfel, P.F., Hakulinen, J., Ku«hn, S., Pangburn,
M.K., Tamerius, J.D. and Meri, S. (1996) FEBS Lett. 393, 297^
302.
[21] Sharma, A.K. and Pangburn, M.K. (1996) Proc. Natl. Acad. Sci.
USA 93, 10996^11001.
[22] Jokiranta, S.T., Hellwage, J., Koistinen, V., Zipfel, P.F. and
Meri, S. (1998) Mol. Immunol. 35, 360.
[23] Ku«hn, S. and Zipfel, P.F. (1995) Gene 162, 225^229.
[24] Hellwage, J., Skerka, C. and Zipfel, P.F. (1997) Immunopharma-
cology 38, 149^157.
[25] Koistinen, V., Wessberg, S. and Leikola, J. (1989) Complement
In£amm. 6, 270^280.
[26] Koistinen, V. (1992) Biochem. J. 283, 317^319.
[27] Eggertsen, G., Hellman, U., Lundwall, A., Folkersen, J. and
Sjoquist, J. (1985) Mol. Immunol. 22, 833^841.
[28] Kyhse-Andersen, J. (1984) J. Biochem. Biophys. Methods 10,
203^209.
[29] Noris, M., Ruggenenti, P., Perna, A., Orisio, S., Caprioli, J.,
Skerka, C., Vasile, B., Zipfel, P.F. and Remuzzi, G. (1999)
J. Am. Soc. Nephrol. 10, 281^293.
[30] Xu, N., Dahlba«ck, B., Ohlin, A.K. and Nilsson, A. (1998) Arte-
rioscler. Thromb. Vasc. Biol. 18, 33^39.
[31] Jenne, D.E., Lowin, B., Peitsch, M.C., Bottcher, A., Schmitz, G.
and Tschopp, J. (1991) J. Biol. Chem. 266, 11030^11036.
[32] Park, C.T. and Wright, S.D. (1996) J. Biol. Chem. 271, 18054^
18060.
[33] Becherer, J.D., Alsenz, J., Esparza, I., Hack, C.E. and Lambris,
J.D. (1992) Biochemistry 31, 1787^1794.
[34] Lambris, J.D., Lao, Z., Oglesby, T.J., Atkinson, J.P., Hack, C.E.
and Becherer, J.D. (1996) J. Immunol. 156, 4821^4832.
[35] Dempsey, P.W., Allison, M.E., Akkaraju, S., Goodnow, C.C.
and Fearon, D.T. (1996) Science 271, 348^350.
FEBS 22986 26-11-99
J. Hellwage et al./FEBS Letters 462 (1999) 345^352352
